- MindBio Therapeutics (CSE:MBIO) recently announced the successful completion of its Phase 1 and 2a clinical trials on depression treatment
- The results have shown significant potential, positioning MB22001, its treatment for major depressive disorder (MDD) as a possible disruptive force in the market for depressive illness treatments
- MindBio has now discovered that the antidepressant effects of MB22001 are sustained well beyond the initial treatment period
- MindBio stock last traded at $0.03 per share
MindBio Therapeutics (CSE:MBIO) recently announced the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
The results, released by the company on Thursday have shown significant potential, positioning MB22001, its treatment for major depressive disorder (MDD), as a useful force in the market for depressive illness treatments.
Promising results from Phase 2a clinical trial
In February 2024, the psychedelic healthcare stock completed its Phase 2a trial of MB22001, focusing on patients with MDD.
Phase 2A follows an extensive phase 1 trial in 80 healthy individuals yielding positive safety and tolerance data. This open-label trial revealed that patients experienced a 60 per cent reduction in depressive symptoms. Notably, 53 per cent of patients who entered the trial with MDD were in remission by the eighth week, with a mean reduction of 14.1 points on the Montgomery-Asberg Depression Rating Scale. This scale is widely recognized for assessing the severity of depressive episodes.
These findings are built on prior trial results that recorded statistically significant improvements in various aspects of well-being. Patients using MB22001 reported better total sleep time and quality, alongside significant increases in subjective feelings of happiness, social connectivity, energy, creativity and overall wellness. Importantly, there was also a noted reduction in anger and irritability.
Sustained antidepressant response
MindBio has now discovered that the antidepressant effects of MB22001 are sustained well beyond the initial treatment period. The positive response in patients persists at one month and three months after the completion of the eight-week treatment cycle. This durability of effect marks a critical advancement in the treatment of MDD, highlighting MB22001’s potential to offer long-lasting relief for patients.
Advancing to Phase 2B trials with breakthrough approvals
After these successful trials, MindBio Therapeutics is moving forward with two significant Phase 2B clinical trials, where dosing is currently underway. The company has also received approval for a third Phase 2B trial focused on women’s health. In a series of world-firsts, each of these trials has been approved for the take-home use of MB22001. This proprietary and self-titratable form of lysergic acid diethylamide (LSD) is designed specifically for safe microdosing at home, a novel approach that sets MindBio apart from its competitors.
Future developments on the horizon
With only a handful of public companies worldwide advancing to Phase 2 and Phase 3 clinical trials in psychedelic medicines, MindBio Therapeutics is solidifying its position as a leader in this emerging field. The company’s innovative approach to treating depressive illness with psychedelic compounds such as MB22001 could significantly alter the landscape of mental health treatment, offering new hope to millions suffering from MDD.
The biopharma company’s thesis is that sub-hallucinogenic microdosing is a safer, scalable and more effective method to administer psychedelic medicine compared with the standard of care, where patients are given large doses in a clinical setting that require six to eight hours of therapeutic assistance.
MindBio is a biotech and biopharma company creating psychedelics-based treatments for mental health conditions. The company is conducting the world’s first take-home LSD microdosing human clinical trials.
MindBio Therapeutics Corp. stock (CSE:MBIO) last traded at $0.03 per share and has risen 20 per cent since the year began.
Join the discussion: Find out what everybody’s saying about this psychedelic stock’s potential treatment against depression on the MindBio Therapeutics Corp. Bullboard, and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo: MindBio Therapeutics)